‘Resilient’ Trials: US FDA Wants To Apply COVID Lessons In Trial Design
Executive Summary
The US FDA is not expecting sponsors to launch ‘pandemic-proof’ trials, but does want to see advance planning so that adaptations can be implemented for unexpected emergencies with ‘less burnout.’